Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
06/30/2025
06/30/2024
06/30/2023
06/30/2022
06/30/2021
Ingresos
3
3
3
3
1
1
Crecimiento de los Ingresos (YoY)
0%
0%
0%
200%
0%
0%
Costo de los ingresos
--
--
--
--
--
--
Utilidad bruta
--
--
--
--
--
--
Venta, General y Administración
9
9
8
8
7
4
Investigación y Desarrollo
--
--
--
--
--
--
Gastos de Operación
11
11
10
9
6
4
Otras Ingresos (Gastos) No Operativos
--
--
--
--
--
--
Ingreso antes de impuestos
-8
-8
-6
-6
-4
-2
Gasto por Impuesto a la Renta
0
0
0
0
0
0
Ingreso Neto
-8
-8
-6
-6
-4
-2
Crecimiento de la Utilidad Neta
33%
33%
0%
50%
100%
100%
Acciones en Circulación (Diluidas)
118.98
134.26
125.84
116.45
105.53
101.7
Cambio de Acciones (YoY)
-6%
7%
8%
10%
4%
16%
EPS (Diluido)
-0.06
-0.06
-0.05
-0.05
-0.04
-0.02
Crecimiento de EPS
19%
19%
-4%
13%
68%
41%
Flujo de efectivo libre
-6
-6
-5
-6
-3
-2
Flujo de efectivo libre por acción
--
--
--
--
--
--
Margen bruto
--
--
--
--
--
--
Margen de operación
-266.66%
-266.66%
-200%
-200%
-400%
-300%
Margen de beneficio
-266.66%
-266.66%
-200%
-200%
-400%
-200%
Margen de flujo de caja libre
-200%
-200%
-166.66%
-200%
-300%
-200%
EBITDA
-8
-8
-6
-6
-4
-3
Margen de EBITDA
-266.66%
-266.66%
-200%
-200%
-400%
-300%
D&A para EBITDA
0
0
0
0
0
0
EBIT
-8
-8
-6
-6
-4
-3
Margen de EBIT
-266.66%
-266.66%
-200%
-200%
-400%
-300%
Tasa de Impuesto Efectiva
0%
0%
0%
0%
0%
0%
Estadísticas clave
Cierre Anterior
$0.26
Precio de apertura
--
Rango del día
-
Rango de 52 semanas
$0.26 - $0.31
Volumen
--
Volumen promedio
16
EPS (TTM)
-0.04
Rendimiento de dividendos
--
Cap. de mercado
$42.6M
¿Qué es PIQLF?
Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bioanalytical services. The company specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. The company focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identifying up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.